{"id":"W1965148683","doi":"10.1016/j.ncl.2010.12.005","title":"Definitions of Breakthrough Disease and Second-Line Agents","year":2011,"lang":"en","type":"review","venue":"Neurologic Clinics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University of Manitoba; Health Sciences Centre","funders":"","keywords":"Medicine; Natalizumab; Observational study; Intensive care medicine; Disease; Mitoxantrone; Randomized controlled trial; Second line; Real world evidence; Clinical trial; First line; Surgery; Internal medicine; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003722526,0.0003760737,0.002019292,0.0001613151,0.00008096523,0.000008820235,0.0002095551,0.0002936523,0.000570258],"category_scores_gemma":[0.003182529,0.0002661549,0.0005577675,0.0002132003,0.0004608161,0.00003195426,0.0004352925,0.0008263554,0.00007422209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001624047,"about_ca_system_score_gemma":0.0002456975,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006127717,"about_ca_topic_score_gemma":0.000006906714,"domain_scores_codex":[0.997543,0.000274615,0.0009825875,0.0005892943,0.0002708253,0.0003396399],"domain_scores_gemma":[0.9970284,0.001273697,0.000467474,0.0007480321,0.0001504927,0.0003319485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001951182,0.0008591936,0.001221206,0.03939174,0.000519399,0.0002178289,0.0000492438,1.271846e-7,2.992822e-7,0.0005120969,0.004128088,0.9529057],"study_design_scores_gemma":[0.0007204216,0.0009089108,0.006590516,0.002072255,0.001972059,0.00003575948,0.000003522988,0.00001206063,9.961126e-8,0.000543685,0.9869477,0.0001929752],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004957036,0.9943941,0.000002827025,0.0001231738,0.0002120948,0.001196207,0.00071358,0.00005324341,0.002809021],"genre_scores_gemma":[0.0003732996,0.9980989,0.0001831229,0.0006065449,0.0001647845,0.0001386432,0.0001917893,0.00004663474,0.0001962796],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9828196,"threshold_uncertainty_score":0.9999791,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5041909961136906,"score_gpt":0.4613418244338931,"score_spread":0.04284917167979746,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}